Literature DB >> 21116742

New daily persistent headache: controversy in the diagnostic criteria.

William B Young1.   

Abstract

New daily-persistent headache is a relatively uncommon type of chronic daily headache. The critical features of the original description and the subsequent Silberstein-Lipton description was the onset:  daily headache starts abruptly without a background of frequent or worsening headache. In 2004, the International Headache Society classification committee excluded an abundance of migrainous features. The exclusion of patients with too many migrainous features from the International Headache Society classification was contentious from the onset and is a source of consternation for many headache experts. Many contend that the sudden onset of a daily headache raises the same issue of what turned on the headache, irrespective of the headache features. Switch-related questions about predisposing factors or precipitating events are equally valid regardless of how many migrainous features the patient has. The differential diagnosis, treatment response, or prognoses do not vary by the number of migrainous features. The current International Headache Society definition excludes more than half of patients with new onset of daily headache. This exclusion due to migrainous features could have adverse scientific, diagnostic, and treatment consequences.

Entities:  

Mesh:

Year:  2011        PMID: 21116742     DOI: 10.1007/s11916-010-0160-4

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  16 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  The classification of chronic daily headache in adolescents--a comparison between the second edition of the international classification of headache disorders and alternative diagnostic criteria.

Authors:  Marcelo E Bigal; Alan M Rapoport; Stewart J Tepper; Fred D Sheftell; Richard B Lipton
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

3.  Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache.

Authors:  T D Rozen; J M Roth; N Denenberg
Journal:  Cephalalgia       Date:  2006-10       Impact factor: 6.292

4.  Chronic daily headache in children and adolescents: a clinic based study from India.

Authors:  A Chakravarty
Journal:  Cephalalgia       Date:  2005-10       Impact factor: 6.292

5.  Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.

Authors:  Y Takase; M Nakano; C Tatsumi; T Matsuyama
Journal:  Cephalalgia       Date:  2004-11       Impact factor: 6.292

6.  Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache.

Authors:  R B Grande; K Aaseth; C Lundqvist; M B Russell
Journal:  Cephalalgia       Date:  2009-11       Impact factor: 6.292

7.  New daily persistent headache in the paediatric population.

Authors:  E Kung; S J Tepper; A M Rapoport; F D Sheftell; M E Bigal
Journal:  Cephalalgia       Date:  2009-01       Impact factor: 6.292

Review 8.  New daily persistent headache.

Authors:  Randolph W Evans
Journal:  Curr Pain Headache Rep       Date:  2003-08

Review 9.  Classification of daily and near-daily headaches: proposed revisions to the IHS criteria.

Authors:  S D Siberstein; R B Lipton; S Solomon; N T Mathew
Journal:  Headache       Date:  1994-01       Impact factor: 5.887

10.  Post-infectious new daily persistent headache may respond to intravenous methylprednisolone.

Authors:  Sanjay Prakash; Nilima D Shah
Journal:  J Headache Pain       Date:  2010-02       Impact factor: 7.277

View more
  2 in total

1.  Does NDPH exist? Some clinical considerations.

Authors:  G C Manzoni; P Torelli
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

2.  [Different headache forms of chapter 4 of the International Headache Classification].

Authors:  A Göbel; A Heinze; H Göbel
Journal:  Schmerz       Date:  2012-12       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.